ledipasvir-sofosbuvir
Selected indexed studies
- Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C. (Drugs, 2018) [PMID:29380288]
- Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C. (Drugs, 2015) [PMID:25837989]
- Ledipasvir-Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection. (Pharmacotherapy, 2016) [PMID:27027412]
_Worker-drafted node — pending editorial review._
Connections
ledipasvir-sofosbuvir is a side effect of
Sources
- Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C. (2018) pubmed
- Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C. (2015) pubmed
- Ledipasvir-Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection. (2016) pubmed
- Ledipasvir/sofosbuvir fixed-dose combination for treatment of hepatitis C virus genotype 4 infection. (2016) pubmed
- Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection. (2015) pubmed
- Drug-Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir. (2018) pubmed
- Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis. (2021) pubmed
- Sofosbuvir and ledipasvir for HIV/HCV co-infected patients. (2016) pubmed
- Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C. (2018) pubmed
- Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C. (2017) pubmed